## Edgar Filing: BIOGEN IDEC INC. - Form 4

BIOGEN IDI Form 4 November 25								
OMB APPROVAL								
	UNITED STATE	Washington, D.C. 20549					3235-0287	
Check thi if no long subject to Section 10 Form 4 or Form 5	6.	SECUI	N BENEFICIAL OWNERSHIP OF RITIES the Securities Exchange Act of 1934.			Expires:January 31, 2005Estimated average burden hours per response0.5		
obligations may continue.Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 1(b).								
(Print or Type R	(esponses)							
Pawlicki Raymond Symbol			<b>d</b> Ticker or Trad INC. [BIIB]	ing	5. Relationship of Reporting Person(s) to Issuer			
(Last)	(First) (Middle)	3. Date of Earliest T			(Check	c all applicable	)	
(Last) (First) (Mondale) 3. Date of (Month/E BIOGEN IDEC INC., 133 BOSTON 11/22/2 POST RD.			Tunsuetton		Director 10% Owner Officer (give title Other (specify below) SVP, Chief Information Officer			
(Street) 4. If Ame Filed(Mon			ate Original ar)		<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> </ul>			
WESTON, N	MA 02493				Form filed by M Person	ore than One Rej	porting	
(City)	(State) (Zip)	Table I - Non-J	Derivative Secu	rities Acq	uired, Disposed of,	or Beneficiall	y Owned	
1.Title of Security (Instr. 3)	any		4. Securities A on(A) or Dispose (Instr. 3, 4 and (A)	ed of (D) 1 5)	5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
		Code V	or		Transaction(s) (Instr. 3 and 4)			
Common Stock	11/22/2013	M <u>(1)</u>	4,000 A	\$ 49.95	12,710.3777	D		
Common Stock	11/22/2013	S <u>(1)</u>	4,000 D	\$ 288	8,710.3777	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

## Edgar Filing: BIOGEN IDEC INC. - Form 4

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number orof Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. l De See (In
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 49.59	11/22/2013		M <u>(1)</u>	4,000	(2)	10/01/2018	Common Stock	4,000	

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Pawlicki Raymond BIOGEN IDEC INC. 133 BOSTON POST RD. WESTON, MA 02493			SVP, Chief Information Officer			
Signatures						

/s/ Matthew S. Gilman, Attorney-in-fact for Raymond Pawlicki

\*\*Signature of Reporting Person

# **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v). \*
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.
- (2) The stock options vest in four (4) equal annual installments commencing one year after the grant date of 10/01/08.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

11/25/2013

Date